Steger, Guenther G <br/><br/>
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.  [electronic resource] 

 -  Clinical breast cancer  02 2018 
 - e41-e47 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0666 
<br/><br/><label>Standard No.: </label>10.1016/j.clbc.2017.05.012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Breast--pathology<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy-Induced Febrile Neutropenia--epidemiology<br/>Disease Progression<br/>Fatigue--chemically induced<br/>Female<br/>Humans<br/>Middle Aged<br/>Progression-Free Survival<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Treatment Outcome<br/>Vinorelbine--therapeutic use